Cytimmune is a pioneering biotechnology company that focuses on developing innovative technologies to treat solid tumor cancers. Their revolutionary IO+ platform has the potential to transform hot tumors into cold ones, reshape the tumor environment, and effectively eliminate cancer cells through multiple mechanisms. The company's lead therapeutic, CYT-6091, is currently undergoing phase 2 clinical studies at the esteemed National Cancer Institute (NCI).

Under new leadership, Cytimmune is driven by a team of experts who possess extensive experience in the biotech and healthcare sectors. From the CEO, Saba Malak, to the President, David Oarr, and the Chief Scientific Officer, Giulio Paciotti, each member plays a vital role in advancing the company's research and development efforts. Cytimmune has garnered outstanding support from prestigious organizations such as the National Institute of Standards and Technology (NIST), the U.

S. Food and Drug Administration, and the Nanotechnology Characterization Lab at the NIH. Moreover, they collaborate with renowned academic partners worldwide.

With a steadfast commitment to innovation and a focus on meeting unmet medical needs, Cytimmune is at the forefront of revolutionizing cancer treatment